| 摘要: | 背景：腸道菌相失調被證實與疾病之間存在密切關係。補充益生菌或益生質可能有助於調節腸道菌相的組成和功能。然而，由於益生菌有效性的影響因素多、加上個體間腸道菌相差異，導致相關研究結果迥異。難消化性麥芽糊精 (RMD) 具有益生質之特性，被添加於本試驗產品中，不過目前對於腸道菌相的研究結果並不一致。因此本試驗目的即為 (1) 探討健康成人攝取益生菌對腸道菌相及其代謝物之影響 (2) 以統合分析釐清 RMD 是否會影響健康成人腸道菌相及代謝物，並結合臨床試驗結果，綜合探討其對腸道健康之影響。材料與方法：招募 20 - 65 歲健康受試者並隨機分派至益生菌或安慰劑組，經 2 週穩定期後，分別介入 4 週總乳酸菌3.6×1010 CFU/day 益生菌或不含菌安慰劑，於試驗前、中、後分析糞便檢體之腸道菌相及短鏈脂肪酸。統合分析以 PICOs (P, Healthy adults; I, RMD; C, pre-RMD; O, Gut microbiota AND SCFAs) 搜尋 2000 年至 2023 年 5 月之相關文獻，並結合臨床試驗結果進行分析。結果：益生菌介入後 Clostridium perfringens、Coliform organisms降低，Bifidobacterium、Coriobacteriales Incertae Sedis、Turicibacter、Acetate 顯著高於安慰劑組。統合分析共納入 6 篇文獻，RMD 介入後顯著增加 Bifidobacterium (Mean difference: 3.11)、降低 Clostridium (Mean difference: -0.43)。結論：健康成人補充益生菌能增加腸道益菌、抑制致病菌，促進短鏈脂肪酸產生；難消化性麥芽糊精會影響健康成人之腸道菌豐富度，為有益於腸道健康的潛在益生質。
Background & Objectives: The relationship between gut dysbiosis and diseases has been confirmed. Supplementing probiotics or prebiotics may help to regulate the composition of gut microbiota. However, effectiveness of probiotics was affected by several factors and gut microbiota among individuals has differences, resulting the different of relevant research results. Resistant maltodextrin (RMD) has been shown to have prebiotic properties and was added to the product of this trial, however, the research results on gut microbiota were inconsistent. Thus, this research aimed to explore the effect of probiotics on gut microbiota and metabolites in healthy adults; combined with the clinical result, a meta-analysis was performed to determine whether the RMD could affect gut health in healthy adults. Methods: Healthy adults were screened and randomly assigned to either the probiotic or placebo group. After a 2-week stabilization period, subjects received either probiotics (Lactic acid bacteria 3.6×1010 CFU/day) or placebo for 4 weeks. Fecal samples were collected at baseline, during, and after the trial for gut microbiota and short chain fatty acids (SCFAs) analysis. A meta-analysis was used PICOs (P, Healthy adults; I, RMD; C, pre-RMD; O, Gut microbiota AND SCFAs) to search the randomized-controlled studies and combined with our clinical trial for analysis. Results: After intervention, Clostridium perfringens and Coliform organisms were significantly decreased compared to that in the baseline; Bifidobacterium, Coriobacteriales Incertae Sedis, Turicibacter, and Acetate were significantly higher than those in the placebo group. A total of 6 studies were included in the present meta-analysis. Results showed that RMD significantly increased Bifidobacterium (Mean difference, MD: 3.11) and decreased Clostridium (MD: -0.43). Conclusion: Probiotics can promote the SCFAs production by increasing beneficial bacteria and inhibiting detrimental bacteria; RMD affect the abundance of gut bacterium in healthy adults. |
